FinancialContent is the trusted provider of stock market information to the media industry.
More NewsRead More
Alnylam Reports Positive Initial Results for ALN-AT3, an Investigational RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders, from Ongoing Phase 1
December 08, 2014
Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting PCSK9 for the Treatment of Hyper
December 11, 2014
Alnylam Files Clinical Trial Application (CTA) for ALN-CC5, an RNAi Therapeutic Targeting Complement C5 in Development for the Treatment of Complement-Mediated Diseases
December 07, 2014
Alnylam to Webcast Presentation at the Oppenheimer 25th Annual Healthcare Conference
December 03, 2014
New Paper in Journal of the American Chemical Society Documents Pioneering Discovery of GalNAc-Conjugated siRNA by Alnylam Scientists
December 01, 2014
Alnylam to Webcast Presentations at Upcoming Investor Conferences
November 25, 2014
Critical Alerts For MannKind, Merck, Alnylam Pharmaceuticals, Nu Skin Enterprises and Organovo Released By InvestorsObserver
December 09, 2014
from PR Newswire
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here